Leading the Way: The CMTA Invests More Than $200K in Cutting-Edge CMT1A Organoid Research

The CMTA’s new $200K+ investment accelerates CMT1A organoid research, revolutionizing

The CMTA Mourns the Loss of Scientific Advisory Board Member and Esteemed CMT Clinical Researcher

It is with the heaviest of hearts that the Charcot-Marie-Tooth

CMT2S Breakthrough

In a recent announcement, Vanda Pharmaceuticals Inc. shared that the

CMTA Alliance Partner, Applied Therapeutics, Announces Positive 12-Month Results in its Ongoing INSPIRE Phase III Trial for SORD-CMT

In a statement released on February 15, 2024, by Charcot-Marie-Tooth

The CMTA Appoints Professor Charlotte Sumner, M.D., to its Scientific Advisory Board

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth

CMTA Awards Over Half a Million Dollars to Fuel Research in Demyelinating Forms of CMT

Multisite and multiyear collaborative project led by a team of

2023 CMTA-STAR Celebrating our Collective Achievements

Significant Research Investment Made in 2023: We are excited to

ToolGen CMT1A Treatment Receives Orphan Drug Designation

CMTA Alliance Partner ToolGen announced December 18, 2023 that it

Pharnext Announces Disappointing Results for CMT1A Drug Trial PXT-3003

Published: December 11, 2023 French biopharmaceutical company Pharnext SA announced

Novartis Secures $1.3B Deal for CMT Treatment CKD-510

Novartis is making significant strides in the field of Charcot-Marie-Tooth